Zevra Therapeutics, Inc. (ZVRA) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | Research and Development Expense |
| Revenue | (m) | |
| Stock-based compensation | 13.13M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 82.38M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $13.13M | $82.38M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | (m) | $12.62M | $-5.43M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | (m) | $12.63M | $-62.94M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | (m) | $12.37M | $-87.67M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | (m) | $15.73M | $-119.12M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | (m) | $15.90M | $-71.88M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | (m) | $14.91M | $-87.00M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | (m) | $12.36M | $-86.74M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | (m) | $7.61M | $-74.80M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | (m) | $7.13M | $-57.26M | $2.05M | (m) | (m) | -27.88× | Reported |
| 2023-12-31 | (m) | (m) | $5.95M | $-49.60M | $1.50M | (m) | (m) | -33.05× | Reported |
| 2023-09-30 | (m) | (m) | $4.04M | $-44.19M | $915.00K | (m) | (m) | -48.29× | Reported |
| 2023-06-30 | (m) | (m) | $3.56M | $-35.45M | $673.00K | (m) | (m) | -52.67× | Reported |
| 2023-03-31 | (m) | (m) | $3.97M | $-53.57M | $512.00K | (m) | (m) | -104.63× | Reported |
| 2022-12-31 | (m) | (m) | $4.29M | $-42.51M | $335.00K | (m) | (m) | -126.88× | Reported |
| 2022-09-30 | (m) | (m) | $4.16M | $-36.09M | $170.00K | (m) | (m) | -212.32× | Reported |
| 2022-06-30 | (m) | (m) | $3.87M | $-31.69M | $52.00K | (m) | (m) | -609.42× | Reported |
| 2022-03-31 | $10.98M | (m) | $2.68M | $-1.09M | $32.00K | (m) | (m) | -34.06× | Reported |
| 2021-12-31 | $10.16M | (m) | $2.44M | $7.73M | $226.00K | (m) | (m) | 34.20× | Reported |
| 2021-09-30 | $10.41M | (m) | $2.07M | $7.36M | $1.39M | (m) | (m) | 5.31× | Reported |
| 2021-06-30 | $9.88M | (m) | $1.83M | $8.37M | $2.54M | (m) | (m) | 3.29× | Reported |
| 2021-03-31 | $8.98M | (m) | $2.14M | $5.13M | $3.72M | (m) | (m) | 1.38× | Reported |
| 2020-12-31 | $8.84M | (m) | $2.49M | $-5.61M | $4.79M | (m) | (m) | -1.17× | Reported |
| 2020-09-30 | $8.25M | (m) | $2.78M | $-6.80M | $4.81M | (m) | (m) | -1.42× | Reported |
| 2020-06-30 | $10.16M | (m) | $3.45M | $-2.36M | $4.85M | (m) | (m) | -0.49× | Reported |
| 2020-03-31 | $13.01M | (m) | $4.15M | $-12.74M | $4.89M | (m) | (m) | -2.61× | Reported |
| 2019-12-31 | $19.41M | (m) | $4.41M | $-20.34M | $4.86M | (m) | (m) | -4.19× | Reported |
| 2019-09-30 | $23.25M | (m) | $4.91M | $-25.20M | $4.91M | (m) | (m) | -5.13× | Reported |
| 2019-06-30 | $32.97M | (m) | $6.44M | $-46.39M | $5.07M | (m) | (m) | -9.15× | Reported |
| 2019-03-31 | $38.65M | (m) | $6.50M | $-52.50M | $5.26M | (m) | (m) | -9.99× | Reported |
| 2018-12-31 | $41.76M | (m) | $6.50M | $-55.90M | $5.47M | (m) | (m) | -10.22× | Reported |
| 2018-09-30 | $40.99M | (m) | $6.39M | $-54.78M | $5.67M | (m) | (m) | -9.66× | Reported |
| 2018-06-30 | $33.95M | (m) | $4.97M | $-46.44M | $5.75M | (m) | (m) | -8.07× | Reported |
| 2018-03-31 | $28.12M | (m) | $4.75M | $-40.76M | $5.78M | (m) | (m) | -7.05× | Reported |
| 2017-12-31 | $20.59M | (m) | $4.56M | $-33.37M | $5.78M | (m) | (m) | -5.78× | Reported |
| 2017-09-30 | $23.02M | (m) | $4.45M | $-36.05M | $5.78M | (m) | (m) | -6.24× | Reported |
| 2017-06-30 | $21.01M | (m) | $6.58M | $-36.84M | $5.77M | (m) | (m) | -6.38× | Reported |
| 2017-03-31 | $21.35M | (m) | $6.67M | $-37.89M | $5.80M | (m) | (m) | -6.53× | Reported |
| 2016-12-31 | $20.47M | (m) | $6.60M | $-37.48M | $5.51M | (m) | (m) | -6.80× | Reported |
| 2016-09-30 | $17.23M | (m) | $6.47M | $-33.93M | $4.76M | (m) | (m) | -7.12× | Reported |
| 2016-06-30 | $17.27M | (m) | $3.68M | $-30.01M | $4.01M | (m) | (m) | -7.48× | Reported |
| 2016-03-31 | $15.05M | $0.00 | $3.30M | $-26.69M | $3.19M | (m) | (m) | -8.37× | Reported |
| 2015-12-31 | $13.93M | $0.00 | $2.37M | $-22.81M | $2.67M | (m) | (m) | -8.54× | Reported |
| 2015-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $11.92M | $0.00 | $214.00K | $-16.44M | $1.60M | (m) | (m) | -10.24× | Reported |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $3.37M | $0.00 | $134.00K | $-4.72M | $157.00K | (m) | (m) | -30.05× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |